Skip to content

    Gujarat Kidney And Super Speciality Limited

    Healthcare
    Healthcare
    ₹128.36
    -3.07% from avg

    Overview

    Price

    ₹128.36

    Market Cap

    ₹1.0k Cr

    Sector

    Healthcare

    Healthcare

    Rank

    5

    Performance

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly

    Balance Sheet

    Balance Sheet

    ₹ Cr · Annual
    Line itemFY23FY24FY25FY26FY26
    LiabilitiesEquity Capital00111116
    Reserves0111422231
    Borrowings0252016
    Other Liabilities4418234
    Total Liabilities4174976266
    AssetsFixed Assets310282926
    CWIP00000
    Investments0020109
    Other Assets171946132
    Total Assets4174976266

    Cash Flow

    Cash Flow

    ₹ Cr · Annual
    Line itemFY23FY24FY25FY26
    ActivitiesCash from Operating0-215-7
    Cash from Investing0-7-19-214
    Cash from Financing0115227
    SummaryCapital Expenditure
    Free Cash Flow0-9-3-8
    FCF Margin

    Valuation

    Assumptions

    Current — GKSL
    Price
    ₹128
    EPS (TTM)
    ₹1.51
    PE (TTM)
    85.0
    Profit growth

    The Earnings Per Share over the last 12 months.

    %

    Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).

    Pre-filled with the lower of median (65.6×) and current (85.0×) PE — the conservative anchor.

    %

    The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.

    Valuation

    Current price
    ₹128
    vs
    Fair value · 15% return
    ₹69
    46%Overvalued

    At 10% growth and a 66× exit, ₹128 only delivers your return if you pay ₹69. The price is currently baking in 23% growth.

    EPS grows 10%/yr for 5 years, then fades to 6% over 2, exits at 66×.

    YearGrowthEPS (₹)
    FY2710.0%1.66
    FY2810.0%1.83
    FY2910.0%2.01
    FY3010.0%2.21
    FY3110.0%2.43
    FY328.0% ·fade2.63
    FY336.0% ·fade2.78

    Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.

    Learn to analyse Gujarat Kidney And Super Speciality Limited

    Guides on how to read this kind of business and the numbers that matter.